Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Giandomenico RovielloElisabetta GambaleRoberta GiorgioneDaniele SantiniMarco StellatoGiuseppe FornariniSara Elena RebuzziUmberto BassoDavide BimbattiLaura DoniGabriella NesiMelissa BersanelliSebastiano ButiUgo De GiorgiLuca GalliAndrea SbranaRaffaele ConcaClaudia CarellaEmanuele NaglieriSandro PignataGiuseppe ProcopioLorenzo AntonuzzoPublished in: Cancer medicine (2022)
After treatment with both nivolumab and cabozantinib, the choice of a safe active systemic therapy offered better outcomes than BSC.